In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
  • Select events

    Select Select events(s)

  • Year

    Select Year(s)

  • Resource type

    Select Resource type(s)

  • Topic

    Select Topic(s)

Filters (0)
  • Select events
  • sub-topic
  • Year
  • Resource type
  • Topic
  • Select events
  • sub-topic
  • Year
  • Resource type
  • Topic

70 results for your search

Frequency, management and outcomes of patients with stable coronary artery disease eligible for COMPASS. An analysis of the CLARIFY registry.

Event : ESC Congress 2019

  • Session : Antithrombotic therapy for coronary artery disease: opportunities and challenges
  • Speaker : E Sorbets (Paris,FR)

Potential real-world benefits of low-dose rivaroxaban in Chinese stable cardiovascular patients

Event : ESC Congress 2019

  • Session : Perspectives on anticoagulation across cardiovascular disease
  • Speaker : B Yan (Hong Kong,HK)

Efficacy and safety of low-dose rivaroxaban on top of aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial

Event : ESC Congress 2020

  • Session : Optimizing Management of Chronic CAD – Squeeze on Big Data for Additional Info
  • Speaker : T Vanassche (Leuven,BE)

Applicability of the COMPASS trial in a Danish all-comers coronary angiography cohort: an analysis of the Western Denmark heart registry

Event : ESC Congress 2018

  • Session : Latest registry data on coronary disease outcomes
  • Speaker : K Olesen (Aarhus N,DK)

CHA2DS2-VASc and CHADS2 scores for risk stratification of major adverse cardiovascular events in the COMPASS trial

Event : ESC Congress 2020

  • Session : Atrial Fibrillation, Platelet Aggregation and Outcomes
  • Speaker : J Sen (Melbourne,AU)

Use of risk score to identify lower and higher risk subsets among COMPASS-Eligible patients with stable CAD. Insights from the CLARIFY Registry

Event : ESC Congress 2019

  • Session : Challenges in contemporary management of coronary artery disease
  • Speaker : G Ducrocq (Paris,FR)

Risk factors and clinical outcomes in chronic CAD and PAD: an analysis of the randomized, double-blind COMPASS trial

Event : ESC Congress 2019

  • Session : Progress in secondary prevention - New treatments
  • Speaker : T Vanassche (Leuven,BE)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are